LENZ Therapeutics, Inc. (LENZ)
NASDAQ (NGS) NASDAQ (NGS) Primary Summary
LENZ Therapeutics, Inc. (LENZ) Q2 2026 Earnings Call Transcript
LENZ Therapeutics, Inc. (LENZ) Q2 2026 Earnings Call Transcript
LENZ Therapeutics Q2 Earnings Call Highlights
LENZ Therapeutics NASDAQ: LENZ reported second-quarter revenue of $5.5 million as it continued the commercial launch of VIZZ, citing modest quarterly growth and a pickup in prescription activity following the July rollout of national television advertising and a telehealth access option.
LENZ Therapeutics, Inc. (LENZ) Reports Q2 Loss, Beats Revenue Estimates
LENZ Therapeutics, Inc. (LENZ) came out with a quarterly loss of $1.02 per share versus the Zacks Consensus Estimate of a loss of $1.21. This compares to a loss of $0.53 per share a year ago.
LENZ Therapeutics, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Curtis Ellergodt Rothschild Investment LLC | 180 | $1,687.3 | $954 | -$733.3 | -43.46% |
| NA Nizar Araji National Bank Of Canada /FI/ | 3,600 | $52,462.5 | $19,296 | -$33,166.5 | -63.22% |
| SN Stephanie Nee HARBOR CAPITAL ADVISORS Inc. | 16,284 | $285,952.03 | $87,282.24 | -$198,669.79 | -69.48% |
 Joseph Castro Nuveen LLC | 46,633 | $1.9M | $242,957.93 | -$1.66M | -87.2% |
 Bobby Adusumilli SJS Investment Consulting Inc. | 11 | $100.65 | $58.3 | -$42.35 | -42.08% |
LENZ Therapeutics, Inc. (LENZ) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has LENZ Therapeutics, Inc. ever had a stock split?
LENZ Therapeutics, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Evert Schimmelpennink CEO | NASDAQ (NGS) Exchange | 52635N103 CUSIP |
| US Country | 152 Employees | - Last Dividend | 22 Mar 2024 Last Split | - IPO Date |
Overview
LENZ Therapeutics, Inc. is a biopharmaceutical entity committed to innovating and bringing to market treatments that enhance vision for patients across the United States. As a company, LENZ Therapeutics is at the forefront of developing pharmacological solutions aimed at addressing various eye conditions, with a significant focus on presbyopia – a common age-related vision issue. With its headquarters nestled in Del Mar, California, the company leverages its strategic location to tap into the bustling biotechnology scene, propelling its research and development efforts to new heights.
Products and Services
- LNZ100
LNZ100 represents one of LENZ Therapeutics, Inc.'s flagship product candidates, currently in Phase III clinical trials. This potential pharmacological solution is designed to tackle the challenges of presbyopia, aiming to restore clarity and focus to those experiencing age-related changes in their vision. By advancing LNZ100 through the stringent Phase III trial phase, LENZ Therapeutics demonstrates its commitment to scientific innovation and patient care.
- LNZ101
Alongside LNZ100, LNZ101 stands as another pivotal product candidate within LENZ Therapeutics, Inc.'s pipeline, also in Phase III clinical trials for the treatment of presbyopia. LNZ101 is aimed at improving vision for those suffering from this age-related vision deterioration, underscoring the company's focused approach in addressing presbyopia through a diverse portfolio of potential treatments. Each product candidate, including LNZ101, is a testament to LENZ Therapeutics' dedication to advancing ocular health and improving the quality of life for patients.
